Showing posts with label medical products. Show all posts
Showing posts with label medical products. Show all posts

Monday, March 18, 2013

N-of-8 application: Exposing unexpected global challenges and opportunities


By its nature, research in health, science, and technology dictates thinking outside the “box” in new and creative ways, seeking fresh perspectives and continuously tapping new innovations for cost-effective and environment-friendly products.

Medical research goes hand in hand with the advent of globalization in the economy, commerce, and societal trends and values. International collaboration in medical research will create fertile conditions for research innovations, understanding, and common solutions to common problems.

The basic logic of N-of-8 New Product Conception applies branding excellence at the international level that is compatible with the global research cooperation in research, development, and scientific activities.

Using N-of-8 should mean that significantly greater financial resources and human intellectual talent can be concentrated on solving the most significant health problems – and increase the timely application of new approaches that would reduce morbidity and mortality in the most significant numbers worldwide.

Obviously, yet importantly, in today’s real-time knowledge sharing, an N-of-8 approach can give a brand team in multiple markets simultaneous access to new product ideas to address similarly demands and issues – motivating the team to more global integration,  more competitiveness, and greater sustainability in product usage.


To work towards creating such vision, N-of-8 can:

Create enabling procedures – the frameworks for research that take into consideration the global market in fostering innovations. Enabling procedures take into consideration the mobility of scientists across borders.

Mobilize human capital – to focus both scientists and marketers, strengthening their collaborative capacity.  Idea generation with cultural competency and sensitivity can lead to successful cross-cultural collaboration.

Build collaboration mechanisms and joint programs – to clearly define goals and processes that lower barriers to product development and enhance synergy.

Systematically address the main barriers that are often issues that lead team down “blind alleys” and block the discussion and dissemination of new ideas and prototypes.  N-of-8 can promote global standardization and harmonization of research knowledge.

Improve idea management and sharing – with a model, tools, and structure for global brand development, creating common standards for documentation and collaboration practices.

Tuesday, March 12, 2013

7 areas of innovative solutions in medical textiles


From Fast Company
Textiles and innovation aren't two words that generally go hand in hand. That's about to change, according to the folks at the European Center of Innovative Textiles (CETI), in Lille, France.

The organization inaugurated its new headquarters last year.  Its goal is creating better, more high-tech solutions across a number of industries. Their current projects show that potential.

Specific to health care, CETI is working to develop new fabric for wound dressing, in which medicine, antivirals, and antibacterials are already integrated into the fibers. Looking further to the future, the organization envisions nonwoven textiles that can be used as a "seed" to rebuild tissue.

Medical, sport & leisure, hygiene, and protection represent over 25% of technical textiles market in value and volume. 

Medical textiles offer innovation solutions in the following application sectors:
  1. wound care,
  2. regenerative medicine,
  3. filtration,
  4. hospital hygiene,
  5. implants,
  6. orthoses and
  7. personal independence

Wednesday, November 09, 2011

$380 million acquisition of Baxa IV pharmacy technology

Baxter International announced its acquisition of Baxa Corporation, a privately held global company based in Englewood, Colo., for a cash consideration of $380 million.  

Baxa develops pharmacy technology that enhances the efficiency and safety of oral and IV dose preparation and delivery.

"The acquisition of Baxa demonstrates Baxter's long-term commitment to nutrition and patient safety and it allows us to offer a broader range of solutions for the safe preparation and delivery of IV medications," said Robert M. Davis, president of Baxter's Medical Products business.  "We believe Baxa's expertise in safely preparing IV and oral liquid medications, and their shared commitment toward improving patient care through innovative drug preparation and delivery technology will benefit patients around the world."

Among the product offerings now part of the Baxter portfolio are the ExactaMix®; Compounder, devices that automate multi-ingredient solution compounding; ExactaMed® Syringes, dispensers that provide greater accuracy for dosing oral liquid medications; NeoThrive® Enteral Feeding System, enteral syringes and accessories; and the DoseEdge® Pharmacy Workflow Manager, an integrated system for managing IV and oral dose preparation activities.

Annual sales for Baxa were $157 million in 2010, and Baxter expects the top-line growth of this business to be accretive to the company's future sales growth.  In addition, Baxter expects this transaction to be dilutive to 2012 earnings by $0.03 to $0.05 per diluted share primarily related to acquisition-accounting and transaction-related expenses.  Excluding these items, the acquisition is neutral to full-year 2012 earnings and increasingly accretive thereafter.  

Baxter's Medical Products business develops and provides products used in the delivery of fluids and drugs to patients.  These include IV solutions and administration sets, premixed drugs and drug-reconstitution systems, IV nutrition products, infusion pumps, inhalation anesthetics and products and services for people with end-stage kidney disease.  At the forefront of IV nutrition, Baxter's ongoing advancements include multi-chamber containers, lipids, amino acids, vitamins and admixing technology.